STAGE IVA PROSTATE CANCER AJCC V8

This study compares two different hormone therapy combinations (leuprolide plus abiraterone vs. relugolix plus abiraterone) in men with advanced prostate cancer who are also receiving radiation therapy. The goal is to see which combination causes less damage to the heart and bloo…

This study tests whether giving abemaciclib before a radioactive drug (177Lu-PSMA-617) can make prostate cancer cells more sensitive to radiation. About 30 men with advanced, treatment-resistant prostate cancer will receive abemaciclib pills for two weeks, then the radioactive th…

This study tests whether adding the drug niraparib to standard hormone therapy after radiation helps control high-risk prostate cancer that hasn't spread far. About 200 men will receive either hormone therapy alone or hormone therapy plus niraparib. The goal is to see if the comb…

This study is for men with prostate cancer that has spread to other parts of the body. It compares standard drug therapy alone versus standard drug therapy plus either surgery to remove the prostate or radiation to the prostate. The goal is to see if adding local treatment helps …

This study tests whether adding the drug apalutamide to standard hormone therapy and radiation helps men with prostate cancer that has spread to lymph nodes after surgery. About 586 participants will receive either the usual treatment or the usual treatment plus apalutamide. The …

This study compares a new, shorter radiation method (5 treatments over 2 weeks) to the usual longer course (20-45 treatments over 4-9 weeks) for men with high-risk prostate cancer. The goal is to see if the shorter schedule works just as well at preventing the cancer from spreadi…

This study tests two drugs, cabozantinib and atezolizumab, in 33 men with a type of advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to see if the combination can stop or shrink tumors. Participants must have non-measurable disease o…

This study tests whether high-dose vitamin D can prevent bone loss in men aged 50+ with prostate cancer who are receiving hormone therapy (ADT). ADT can weaken bones, raising the risk of fractures. Researchers will give 240 participants either high-dose vitamin D or a placebo for…

This study tests whether adding the drug talazoparib to standard hormone therapy can better control advanced prostate cancer that still responds to hormone treatment. About 70 men with cancer that has spread will receive the combination. The goal is to see if this approach lowers…

This study tests whether a combined PET/MRI scan using a radioactive tracer can accurately detect if prostate cancer has spread to nearby lymph nodes. Fifty men with high-risk localized prostate cancer will receive the scan before their planned prostate removal surgery. The resul…

This study tests whether adding a freezing procedure called cryoablation to standard radiation therapy can better relieve pain from cancer that has spread to the bones. About 40 adults with certain cancers (like prostate, kidney, or melanoma) that have spread to the bone will be …

This study looks at why some prostate cancers become resistant to a targeted radiation treatment called 177Lu-PSMA. Researchers will take small tissue samples (biopsies) from tumors in 30 patients before and after therapy. The goal is to find genetic changes that cause resistance…